Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Nuclear Medicine and Molecular Imaging
Erschienen in: Nuclear Medicine and Molecular Imaging 1/2020

22.01.2020 | Case Report

Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide

verfasst von: Abhishek Jha, Mayank Patel, Eva Baker, Melissa K. Gonzales, Alexander Ling, Corina Millo, Marianne Knue, Ali Cahid Civelek, Karel Pacak

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

We describe an unusual case of a 42-year-old female with an unresectable succinate dehydrogenase subunit B (SDHB)-related pterygopalatine fossa paraganglioma. She underwent somatostatin receptor imaging with 68Ga-DOTA(0)-Tyr(3)-octreotate (68Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT), which showed uptake in the above mentioned tumor. Hence, the patient was started on octreotide, a cold somatostatin analog, and responded with tumor stabilization and improvement of clinical symptoms for 36 months since initiation of octreotide therapy. This case demonstrates the role of 68Ga-DOTATATE PET/CT in diagnostic localization and its subsequent role in treatment using cold somatostatin analog as a potential choice of therapy in the management of paraganglioma in an unusual location with limited therapeutic options.
Literatur
1.
Martin TP, Irving RM, Maher ER. The genetics of paragangliomas: a review. Clin Otolaryngol. 2007;32:7–11.CrossRef
2.
TaïebD KA, Boedeker CC, Martucci V, Fojo T, Adler JR Jr, et al. Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev. 2014;35:795–819.CrossRef
3.
Sykes JM, Ossoff RH. Paragangliomas of the head and neck. Otolaryngol Clin N Am. 1986;19:755–67.
4.
Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, et al. 68Ga-DOTATATE PET/CT in the localization of head and neck Paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med. 2016;57:186–91.CrossRef
5.
Erickson D, Kudva YC, Ebersold MJ, Thomson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210–6.CrossRef
6.
Capitana C, Ntali G, Karavitaki N, Grossman AB. The management of head-and-neck paragangliomas. Endocr Relat Cancer. 2013;20:R291–305.CrossRef
7.
McCrary HC, Babajanian E, Calquin M, Carpenter P, Casazza G, Naumer A, et al. Characterization of malignant head and neck Paragangliomas at a single institution across multiple decades. JAMA Otolaryngol Head Neck Surg. 2019;145:641–6.CrossRef
8.
Jha A, Nilubol N, and Pacak K. Some Considerations in Treating Malignant Head and Neck Paragangliomas at a Single Institution Across Multiple Decades. JAMA Otolaryngol Head Neck Surg. 2019 Nov 14. doi: 10.1001/jamaoto.2019.3444. [Epub ahead of print]CrossRef
9.
Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–46.CrossRef
10.
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRef
11.
Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68Ga-DOTA-conjugated Somatostatin receptor targeting peptide PET in detection of pheochromocytoma and Paraganglioma: a systematic review and meta-analysis. J Nucl Med. 2019;60:369–76.CrossRef
12.
Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2015;21:3888–95.CrossRef
13.
Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FL, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43:1784–91.CrossRef
14.
Jha A, Ling A, Millo C, Gupta G, Viana B, Lin FI, et al. Superiority of (68)Ga-DOTATATE over (18)F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging. 2018;45:787–97.CrossRef
15.
Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, Ling A, et al. Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic Pheochromocytoma and Paraganglioma. Front Oncol. 2019;9:53.CrossRef
16.
Jha A, Ling A, Millo C, Chen C, Gupta G, Viana B, et al. Superiority of 68Ga-DOTATATE PET/CT to other functional and anatomic imaging modalities in the detection of SDHD-related pheochromocytoma and paraganglioma – A comparative prospective study. J Nucl Med. May 1, 2018 vol. 59 no. supplement 1 46
17.
Taieb D, Hicks RJ, Hindie E, Guillet BA, Avrram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112–37.CrossRef
18.
*Taïeb D, *Jha A, Treglia G, and Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2019;27:R627–R652.
19.
Puranik AD, Kulkarni HR, Singh A, et al. Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours). Eur J Nucl Med Mol Imaging. 2015;42:1223–30.CrossRef
20.
Tenenbaum F, Schlumberger M, Lumbroso J, Parmentier C. Beneficial effects of octreotide in a patient with a metastatic paraganglioma. Eur J Cancer. 1996;32A:737.CrossRef
21.
Tonyukuk V, Emral R, Temizkan S, Sertcelik A, Erden I, Corapcioglu D. Case report: patient with multiple paragangliomas treated with long acting somatostatin analogue. Endocr J. 2003;50:507–13.CrossRef
22.
Duet M, Guichard JP, Rizzo N, Boudiaf M, Herman P. Tran Ba Huy P. are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas? Laryngoscope. 2005;115:1381–4.CrossRef
23.
van Hulsteijn LT, van Duinen N, Verbist BM, Jansen JC, van der Klaauw AA, Smit JW, et al. Effects of octreotide therapy in progressive head and neck paragangliomas: case series. Head Neck. 2013;35:E391–6.CrossRef
24.
Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63.CrossRef
25.
Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.CrossRef
Metadaten
Titel
Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide
verfasst von
Abhishek Jha
Mayank Patel
Eva Baker
Melissa K. Gonzales
Alexander Ling
Corina Millo
Marianne Knue
Ali Cahid Civelek
Karel Pacak
Publikationsdatum
22.01.2020
Verlag
Springer Singapore
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 1/2020
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-019-00629-3

Weitere Artikel der Ausgabe 1/2020

Nuclear Medicine and Molecular Imaging 1/2020 Zur Ausgabe

Case Report

Isolated Hepatic Metastasis of Prostate Cancer with Variable 18F-fluociclovine Uptake by PET/CT Imaging

Case Report

Malignant Transformation of an Epidermoid Cyst in an Intrapancreatic Accessory Spleen: A Case Report

Review

Bone SPECT/CT of the Foot and Ankle: Potential Clinical Application for Chronic Foot Pain

Original Article

Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response

Original Article

Prognostic Value of Bone Marrow F-18 FDG Uptake in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma

Interesting image

Clinical Applications of 68Ga-PSMA PET/CT on Residual Disease Assessment of Juvenile Nasopharyngeal Angiofibroma (JNA)